Previous Close | 15.10 |
Open | 14.92 |
Bid | 14.83 x 1200 |
Ask | 16.66 x 800 |
Day's Range | 14.71 - 15.94 |
52 Week Range | 11.70 - 31.41 |
Volume | |
Avg. Volume | 336,750 |
Market Cap | 416.921M |
Beta (5Y Monthly) | 2.55 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.29 |
Earnings Date | Mar 28, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 39.83 |
Subscribe to Yahoo Finance Plus to view Fair Value for ARCT
Immuneering Corporation (IMRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
SAN DIEGO, March 07, 2023--Arcturus Therapeutics Holdings Inc. (the "Company," "Arcturus," Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2022 after the market close on Tuesday, March 28 and will also host a conference call and webcast
SAN DIEGO, February 06, 2023--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences: